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The relative contribution of T-cell produced effector molecules to tumour rejection is 
unclear, but interferon-γ  (IFNγ) is critical in most models analysed1. While IFNγ  can 
impede tumour growth by directly acting on the cancer cells2,3, it has to act on the 
tumour stroma for rejection of large established tumours4,5. However, which stroma 
cells have to respond to IFNγ  and by which mechanism IFNγ  contributes to tumour 
rejection through stromal targeting remained elusive. Here, we used a model of IFNγ  
and IFNγ-GFP fusion protein induction in large vascularized tumours, growing in mice 
expressing the IFNγ  receptor exclusively in defined cell types. Neither responsiveness to 
IFNγ  by myeloid cells, other hematopoietic cells including T cells or fibroblasts was 
sufficient for IFNγ-induced tumour regression, while responsiveness to IFNγ  by 
endothelial cells was necessary and sufficient. Intra-vital microscopy revealed IFNγ-
induced regression of the tumour vasculature, resulting in blood flow arrest and 
subsequent tumour collapse, similar to non-haemorrhagic necrosis in ischemia but 
unlike haemorrhagic necrosis induced by tumour necrosis factor (TNF). The early 
events of IFNγ-induced tumour ischemia resemble non-apoptotic blood vessel regression 
during development, wound healing or IFNγ-mediated, pregnancy-induced remodelling 
of uterine arteries6-8. 
 
The contribution of T-cell effector molecules to tumour rejection has mainly been studied in 
models of low tumour burden with little tumour stroma1,9. For IFNγ-mediated effects, various 
cell types have been suggested as targets, such as the cancer cells themselves, macrophages, 
fibroblasts, monocytes or endothelial cells10-18. Most cells express the IFNγ receptor (IFNγR). 
IFNγ inhibits neo-angiogenesis and prevents the development of tumours from inoculated 
cancer cells12,13, but which effect IFNγ has on the blood vessels of large established tumours 
is poorly understood. Since human cancers are usually at least one centimetre in diameter 
when first detected, studying the effects of IFNγ on the vasculature of such tumours is 
clinically relevant. We transduced the fibrosarcoma cell line MCA313, derived from a 
methylcholanthrene-treated IFNγR-deficient C57BL/6 (IFNγRdel) mouse, with a retrovirus 
allowing doxycycline (dox)-mediated regulation of IFNγ expression (MCA313IFNγ-IND)19,20 
(Fig. 1a). MCA313IFNγ-IND cells produced IFNγ upon dox treatment (∼87 ng/ml), but not in its 
absence (Fig. 1b). When IFNγ was induced in large MCA313IFNγ-IND tumours in Rag-deficient 
(Ragdel) mice, serum levels reached a peak of ∼10 ng/ml 48 h after dox administration (Fig. 
1c). Induction of IFNγ in 3 weeks-old large MCA313IFNγ-IND tumours in C57BL/6 wild type 
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(WT) mice led to tumour regression, macroscopic as well as microscopic necrosis and loss of 
tumour endothelial (CD31+) cells (Extended Data Fig. 1a-c). Tumour regression was observed 
in WT but not in IFNγRdel mice (Extended Data Fig. 1a). MCA313IFNγ-IND tumours grew with 
similar kinetics and regressed similarly upon IFNγ induction in WT and Ragdel mice, 
indicating their low immunogenicity (Extended Data Fig. 1a). To determine whether dox-
induced IFNγ levels were comparable to those achieved by antigen-specific T cells rejecting 
established tumours of a similar size, we treated Ragdel mice bearing 16.113 tumours with 
TCR-I CD8+ T cells specific for SV40 Large T antigen expressed by the cancer cells and 
determined IFNγ serum levels 3-7 days after T-cell transfer. On day 4, ∼13 ng/ml IFNγ were 
detected (Fig. 1c) and tumours were subsequently rejected (Extended Data Fig. 1d). Thus, 
IFNγ expression in large MCA313IFNγ-IND tumours was comparable to that of effector T cells 
during tumour rejection and was sufficient to induce tumour regression, if only tumour stroma 
but not cancer cells could respond to IFNγ. Similarly, IFNγ induction in large IFNγ-
insensitive 16.113-999IFNγ-IND adenocarcinomas resulted in tumour regression and a reduction 
in tumour endothelial cells (Extended Data Fig. 1e-g). 
To identify the stromal target cells of IFNγ, we generated mice with exclusive IFNγR 
expression in defined cell types. In these mice, the IFNγR transgene is linked to a GFP 
reporter gene by an internal ribosome entry site (IRES) and separated from a ubiquitous 
promoter by a Cre recombinase-excisable stop cassette (pCAGloxPStoploxP-IFNγR-IRES-GFP, 
termed PIG mice, Fig. 1a and Extended Data Fig. 2a). The mice were crossed to IFNγRdel 
mice to inactivate their endogenous IFNγR gene (PIGIFNγR-del). Expression of the Cre 
recombinase in fibroblasts from PIGIFNγR-del mice led to IFNγR (CD119) and GFP expression 
(Extended Data Fig. 2b). IFNγ up-regulated MHC-I comparable to WT fibroblasts, 
demonstrating function and tight regulation of the IFNγR (Extended Data Fig. 2c). We 
generated PIGIFNγR-del x CMV-Cre (PIGCmv-Cre) mice with ubiquitous Cre recombinase 
expression. Most stroma cells of MCA313IFNγ-IND tumours grown in PIGCmv-Cre mice were 
GFP+, as analysed for CD11b+ (myeloid), F4/80+ (macrophages), CD31+ (endothelial), and 
FAP+ (mesenchymal) cells (Extended Data Fig. 2d). Most cells in the peripheral blood (T 
cells, B cells, NK cells, CD11b+, CD11c+, GR1+ cells) were GFP+ (Supplementary Data Table 
1a).	   No GFP+ cells were detected in MCA313IFNγ-IND tumours of PIGIFNγR-del mice 
(Supplementary Data Table 1b and Extended Data Fig. 2e). Dox-induced IFNγ expression in 
large MCA313IFNγ-IND tumours in PIGCmv-Cre but not in PIGIFNγR-del mice induced necrosis, loss 
of endothelial cells and tumour regression, indicating that the model allowed the identification 
of the stromal targets of IFNγ (Fig. 1d-i). 
	   4	  
Since (Tie2+) macrophages support neo-vascularization in tumours21 but can also 
secrete anti-angiogenic cytokines in response to IFNγ14,15, we analysed PIGIFNγR-del x Lys-Cre 
(PIGLys-Cre) mice with exclusive IFNγR expression in cells of the myeloid lineage 
(Supplementary Data Table 1a). In MCA313IFNγ-IND tumours, most CD11b+ and F4/80+ cells, 
but not CD31+ or FAP+ cells, were GFP+ and, thus, IFNγ-responsive (Extended Data Fig. 3a). 
IFNγ induction in established MCA313IFNγ-IND tumours of PIGLys-Cre mice neither induced 
necrosis, nor reduced numbers of endothelial (CD31+) cells, nor delayed tumour growth (Fig. 
2a-c). Thus, exposing exclusively myeloid cells in established tumours to IFNγ does not lead 
to cancer regression. 
We generated PIGIFNγR-del x FSP-Cre (PIGFsp-Cre) mice in which one fourth of tail 
fibroblasts and most haematopoietic cells but not endothelial cells expressed GFP and, thus, 
the IFNγR (Extended Data Fig. 3b and Supplementary Data Table 1a). In MCA313IFNγ-IND 
tumours, CD11b+, F4/80+ and FAP+ cells, but not CD31+ cells had recombined, as indicated 
by GFP expression (Extended Data Fig. 3c). IFNγ induction in established MCA313IFNγ-IND 
tumours of PIGFsp-Cre mice did not lead to macroscopic necrosis, microscopic endothelial cell 
loss or tumour regression (Fig. 2d-f). To confirm that IFNγ-signalling in T cells does not 
contribute to blood vessel reduction, we reconstituted Ragdel or Ragdel x IFNγRdel mice with 
WT splenocytes and induced IFNγ in established MCA313IFNγ-IND tumours. Only in T cell-
reconstituted Ragdel but not Ragdel x IFNγRdel recipients endothelial cell numbers were 
reduced after IFNγ induction (Extended Data Fig. 3d). Thus, IFNγ responsiveness by tumour-
associated fibroblasts, T cells or hematopoietic cells was not sufficient for IFNγ-induced 
tumour necrosis or regression. 
Next, we analysed mice with selective IFNγR expression in endothelial cells using 
PDGFB-CreER-IRES-GFP mice. Because these mice, in which recombination is tamoxifen-
inducible in PDGFB+ cells, and PIGIFNγR-del mice both carry GFP reporter genes, 
recombination was analysed in tamoxifen-treated PDGFB-CreER-IRES-GFP x Rosa26-RFP 
mice bearing large MCA313IFNγ-IND tumours. Around 75.4% of tumour endothelial cells 
(CD31+/CD146+) had recombined, indicated by RFP expression (Extended Data Fig. 4a, b). 
To avoid confounding effects by endogenous IFNγ (Extended Data Fig. 4c-g), experiments 
were performed in quadruple PIGIFNγR-del x PDGFB-CreER-IRES-GFP x IFNγdel (PIGPdgfb-Cre-
IFNγ-del) transgenic mice, which are deficient in IFNγ and IFNγR expression and allow 
selective induction of IFNγR expression in endothelial cells. GFP was almost exclusively 
expressed in tumour endothelial cells and faithfully monitored IFNγR expression (Extended 
Data Fig. 5a, b). The few GFP+ CD11b+ cells did not respond to IFNγ with INOS induction 
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(Supplementary Data Table 1b and Extended Data Fig. 5c). IFNγ induction in large 
MCA313IFNγ-IND tumours in tamoxifen-treated PIGPdgfb-Cre-IFNγ-del mice induced necrosis, 
disappearance of endothelial cells and tumour regression (Fig. 2g-i). Following regression, 
tumours slowly resumed growth (Fig. 2i). However, these tumours contained large central 
necrotic areas with viable cells at the rim (Extended Data Fig. 5d, e). As opposed to 
endothelial cells without IFNγ induction, endothelial cells in tumours exposed for ∼ 50 days 
to IFNγ were mostly GFP-, suggesting a strong selective pressure against IFNγR-expressing 
endothelial cells (Fig. 2j). In line with this assumption, tumours grown for 50-100 days in 
PIGPdgfb-Cre or PIGCmv-Cre mice still produced inducible IFNγ in vitro (Extended Data Figure 
5f). After five days of IFNγ exposure, endothelial cells (CD31+/CD146+) in MCA313IFNγ-IND 
tumours of all mice investigated in this study were reduced by 80-90% only in those lines, in 
which endothelial cells could respond to IFNγ (Fig. 2k). To ask whether T cell-derived IFNγ 
similarly affects endothelial cells, Ragdel mice bearing 16.113 tumours were treated with 
IFNγ-competent or -deficient TCR-I CD8+ T cells. Five days after T cell transfer, we found a 
significantly lower number of endothelial cells in tumours treated with WT than with IFNγ-
deficient T cells (Extended Data Fig. 1h). Together, IFNγR responsiveness by tumour 
endothelial cells was necessary and sufficient for necrosis and tumour regression.  
We intravitally imaged the same area of tumours that were growing behind a glass 
window over several days22. To better assess the kinetics of vascular regression by IFNγ, a 
dox-inducible IFNγ-GFP fusion gene was introduced into plasmacytoma J558L cells 
(J558LIFNγ-GFP-IND), which are resistant to cytotoxic effects of IFNγ and TNF (see below)23. To 
monitor cancer cells, J558LIFNγ-GFP-IND cells additionally expressed the fluorescent (cerulean) 
protein. J558LIFNγ-GFP-IND cells produced ∼104 ng/ml biologically active IFNγ-GFP (Fig. 3a, b) 
and could be visualized by intravital microscopy (Supplementary Information Video 1 and 2). 
Its induction in established J558LIFNγ-GFP-IND tumours growing in Ragdel mice led to tumour 
regression (Extended Data Fig. 6a). Large vascularized J558LIFNγ-GFP-IND tumours growing 
behind a window were imaged for 6 days following dox application. A GFP signal was 
observed 24 h after IFNγ-GFP induction, and vascular density decreased with a loss of 
smaller blood vessels and thinning of larger vessels (Fig. 3c). At 48 h, blood vessels further 
decreased and were undetectable by 96 h of dox treatment. As shown by loss of cerulean 
signal, cancer cells were destroyed subsequent to blood vessel regression (Fig. 3d and 
Extended Data Fig. 6b). DiD-labelled erythrocytes, injected before imaging, did not leak from 
the tumour vessels during the entire longitudinal imaging. Instead, the blood flow ceased with 
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progressing vessel regression (Supplementary Information Video 3). Thus, IFNγ induced 
tumour ischemia. 
We performed similar experiments with TNF, which is usually produced 
simultaneously with IFNγ by activated T cells. Therefore, cerulean+ J558LTNF-GFP-IND cells 
with an inducible TNF-GFP fusion protein were generated. J558LTNF-GFP-IND produced ∼368 
pg/ml biologically active TNF-GFP upon dox application (Fig. 3e, f). Induction of TNF-GFP 
in established J558LTNF-GFP-IND tumours growing in Ragdel mice led to tumour regression 
(Extended Data Fig. 7a). Imaging revealed strikingly different changes caused by TNF-GFP 
compared to IFNγ-GFP. The TNF-GFP signal was observed after 24 h. Blood vessels did not 
become thinner but, if anything, wider (Fig. 3g and Extended Data Fig. 7b). By ∼36 h after 
TNF-GFP induction, the blood vessels burst and DiD-labelled erythrocytes leaked into the 
tumour tissue (Supplementary Information Video 4). Cancer cells decayed subsequent to 
vessel burst (Fig. 3h). In J558LTNF-GFP-IND tumours, erythrocytes were dispersed throughout 
the tissue 48 h after TNF-GFP induction, whereas in J558LIFNγ-GFP-IND tumours they remained 
within blood vessels (Extended Data Fig. 8a, b). Together, necrosis caused by IFNγ was 
induced by ischemic shutdown of perfusion rather than by bursting of the blood vessels as 
observed for TNF.  
Endothelial cells in kidney and spleen of WT mice 5 days after dox treatment were 
unaltered (Extended Data Fig. 9a), indicating a relative selective effect on the (activated) 
tumour vasculature. Gene expression profiling of normal kidney and tumour endothelial cells 
revealed 1500 differentially expressed genes. After IFNγ induction, the expression of 356 
genes changed in kidney and 42 in tumour endothelial cells. Only 17 genes were exclusively 
regulated in tumour endothelial cells (Extended Data Fig. 9b). Activated endothelium occurs 
physiologically, e.g. during development, pregnancy-induced vascular remodelling and 
wound healing. In PIGPdgfb-Cre-IFNγ-del mice and WT mice with elevated IFNγ levels from small 
MCA313IFNγ-IND tumours, wounds did not heal in contrast to IFNγRdel mice, suggesting a 
selective effect of IFNγ on activated endothelium (Extended Data Fig. 5 g, h). To further 
elaborate on this hypothesis, we determined the gene expression profile of IFNγ-exposed 
endothelial cells of MCA313IFNγ-IND and J558LIFNγ-GFP-IND tumours as well as 16.113 tumours 
treated by adoptive T cell therapy (Extended Data Fig. 9c and Supplementary Table 2). 
Endothelial cells from all three tumours showed strong similarity in regulated genes. Genes 
associated with immune regulation and migration, e.g. CXCL10 and CXCL11 (Extended Data 
Fig. 9c and Supplementary Data Table 2) were highly regulated. It is well-established that 
CXCL10 acts anti-angiogenic on tumour blood vessels and is involved in physiological vessel 
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regression, but it was surprising that it is produced by the tumour endothelial cells 
themselves7,14-16.  
We did not observe apoptosis-associated genes to be highly regulated in IFNγ-exposed 
endothelial cells (Supplementary Table 2). Rather, IFNγ-exposed endothelial (ERG+ or 
CD31+) cells in MCA313IFNγ-IND tumours gradually decreased over a five-days period 
(Extended Data Fig. 10a-e). Even though the total cleaved caspase 3+ (CC3+) area increased 
(Extended Data Fig. 10f), the number of CC3+ endothelial cells did not (Extended Data Fig. 
10c). Endothelial cells significantly decreased not only in necrotic but also in vital tumour 
tissue (Extended Data Fig. 10b). Reduction in endothelial cells preceded decrease in collagen 
4 (Extended Data Fig. 10g-i). NG2+ pericytes did not decrease (Extended Data Fig. 10j, k), 
and we did not observe reduced co-localization with endothelial cells (Extended Data Fig. 
10l). Therefore, we assume that primarily pericyte-uncovered endothelial cells disappeared 
during the first five days of IFNγ exposure. IFNγ exposure led to rapid rounding and 
condensation of CD31+ and VE-cadherin+ endothelial cells in MCA313IFNγ-IND tumours, 
similar as observed for regressing blood vessels during the ovarian cycle (Extended Data Fig. 
10m)24,25. In line with earlier studies on physiological blood vessel regression25, electron 
microscopy showed that the vessels were more frequently occluded upon IFNγ exposure 
(Extended Data Figure 10n, o). IFNγ induced also profound morphological changes of human 
umbilical vein endothelial cells in vitro without indication of apoptosis (Extended Data Fig. 
9e and Supplementary Information Video 5). In the J558L model, we confirmed reduction of 
endothelial (ERG+ or CD31+) cells by IFNγ-GFP fusion protein (Extended Data Fig. 6c-g) 
and found that TNF-GFP did not significantly change endothelial cell numbers during the first 
five days of cytokine exposure (Extended Data Fig. 7f, g). Collectively, we observed a 
process, which involves lumen collapse/vessel occlusion and progressive disappearance of 
first small and then large calibre vessels. These characteristics of controlled blood vessel 
regression suggest that IFNγ induces changes in the tumour vasculature similar to those 
observed during physiological blood vessel regression. Irf4, up-regulated by IFNγ in tumour 
but not normal endothelial cells (Extended Data Fig. 9b, c, Supplementary Table 2), has not 
been reported to be induced by IFNγ in (tumour-) endothelial cells. It was induced in vitro by 
IFNγ in mouse endothelial cells (Extended Data Fig. 9f). Endothelial cells in large 
MCA313IFNγ-IND tumours two days after IFNγ induction in Irf4-deficient mice revealed a more 
pronounced vessel reduction (Extended Data Figure 9g, h) and an increased number of 
apoptotic endothelial cells compared to those in WT mice (Extended Data Fig. 9i, j), 
reminiscent to the protective role of IRF4 for neurons in ischemia26. 
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We showed that ischemia, a pathological reaction, is beneficial in anti-tumour 
responses. Both, IFNγ and TNF destroy tumour blood vessels, yet by different mechanisms 
and with different consequences. IFNγ released by the tumour did not lead to systemic 
toxicity in mice with selective IFNγR expression on endothelial cells, as observed in WT 
mice, which is compatible with the observation that IFNγ, unlike TNF, does not induce 
necrosis in combination with bacterial products in the normal skin27. The early events induced 
by IFNγ in tumours resemble blood vessel regression in development, wound healing, ovary 
cycle and pregnancy-induced uterine vascular remodelling, the latter being regulated by 
IFNγ6-8,24,25. In conclusion, IFNγ and TNF, simultaneously produced by effector T cells, are a 
powerful team: 1. TNF bursts the tumour vessels and allows extravasation of infiltrating cells, 
and 2. IFNγ helps to prevent relapse by keeping the tumour in an ischemic state, similar as 
observed when targeting these cytokines selectively to the vasculature28.  
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Figure legends 
 
Figure 1 ┃ Reductionist model to identify the stromal target for IFNγ-induced tumour 
regression. 
a, Experimental system consisting of IFNγRdel cancer cells, MCA313, with dox-inducible 
IFNγ expression (MCA313IFNγ-IND) and transgenic mice with inducible IFNγR expression in 
defined cell types (PIG mice: Cre/LoxP-excision of stop-cassette allows CAG-promoter 
driven expression of IFNγR and GFP on an IFNγRdel genetic background). b, Dox-dependent 
IFNγ expression by MCA313IFNγ-IND cells in vitro (ELISA, mean and SD of 3 experiments). c, 
Similar IFNγ serum peak levels produced by MCA313IFNγ-IND  (but not MCA313) tumours 
(peak day 2 after dox, tumours 790 ± 260 mm3, filled circles, n = 9) and CD8+ T cells during 
rejection of 16.113 tumours (peak day 4 after ATT, tumours 584 ± 153 mm3, open circles, n = 
16), mean ± s.e.m. d - f, Dox-induced IFNγ expression in MCA313IFNγ-IND tumours of PIGCmv-
Cre mice leads to d, necrosis (n = 2). e, blood vessel reduction (n = 2) within 120 h and f, 
tumour regression after dox application at a tumour size of 613	 ± 467 mm3 (n = 7). 
Combined data of 2 experiments. g – i, No effect as in d - f in control PIGIFNγR-del mice. d and 
g, size bar 0.5 cm. i, dox at a tumour size of 562 ±	 65 mm3 (n = 7). Combined data of 2 
experiments. The number of mice, replications and sample size for each experiment are 
shown in Supplementary Table 3. 
 
Figure 2 ┃ IFNγ-responsiveness by endothelial cells is necessary and sufficient for 
necrosis, blood vessel reduction, and tumour regression by IFNγ.  
 Following IFNγ induction in MCA313IFNγ-IND tumours of (a-c) PIGLys-Cre and (d-f) PIGFsp-Cre 
mice, no necrosis, changes in blood vessel density (120 h after dox) or tumour regression was 
observed. c, f, Dox at a tumour size of 616 ± 183 mm3 and 599 ± 175 mm3, respectively (n = 
7-8). Combined data of 2 experiments. g - j, To induce CreER-mediated recombination in 
endothelial cells, PIGPdgfb-Cre-IFNγ-del mice received tamoxifen. g, necrosis and h, reduction in 
blood vessels 120 h after IFNγ induction. i, Tumour growth is delayed after IFNγ induction 
(right panel) in MCA313IFNγ-IND tumours (519 ± 30 mm3, n = 6) grown in PIGPdgfb-Cre-IFNγ-del 
mice compared to control mice (left panel). Starting day 21, tumour size differs significantly 
(**). j, Flowcytometry of tumour endothelial cells (CD31+/CD146+) of tumours depicted in i, 
shows that most endothelial cells in untreated tumours (app. day 20) are GFP+, while most 
endothelial cells are GFP- in tumours after 48 ± 5 days IFNγ exposure. k, 107 tumour cells of 
indicated mice without (open bars) and 120 h after IFNγ induction (black bars), were analysed 
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for CD31+/CD146+ cells using flowcytometry. Size bar in a, d, g, 0.5 cm. Data are mean ± 
SD, ** P<0.01 and *** P<0.001. The number of mice, replications and sample size for each 
experiment are shown in Supplementary Table 3. 
 
Figure 3 ┃ Tumour ischemia versus tumour necrosis induced by intratumoural IFNγ-
GFP or TNF-GFP fusion proteins, respectively.  
a, IFNγ-GFP induction in cerulean+ J558LIFNγ-GFP-IND cells 48 h after dox, analysed for IFNγ 
(ELISA, left y-axis and open bars) and GFP (flowcytometry, right y-axis and black bars). 
Mean ± SD of 3 experiments. b, Up-regulation of MHC-I on B16-F10 cells by IFNγ-GFP is 
comparable to recombinant IFNγ. Cells cultured with (black line) or without (dotted line) 1 
ng/ml IFNγ (left panel) or IFNγ-GFP (right panel), were analysed for H-2Kb/H-2Db 
expression (1 representative of 2 experiments). c, The same area of J558LIFNγ-GFP-IND tumours 
established for 12-14 days behind a glass window in Ragdel mice was repeatedly imaged over 
several days following dox. Shown: cancer cell viability (cerulean+, 1st row), IFNγ-GFP 
expression (2nd row), vascular density (bright field, 3rd row) and blood flow (DiD-stained 
erythrocytes, 4th row) (see also Extended Data Fig. 8 and Supplementary Information Video 
3). d, Quantification of changes in J558LIFNγ-GFP-IND tumour signal and blood vessel area over 
time. e, TNF-GFP induction in cerulean+ J558LTNF-GFP-IND cells 48 h after dox, analysed as in 
a except for TNF ELISA (mean ± SD). f, Cytotoxicity of TNF-GFP towards L929 cells is 
comparable to recombinant TNF. L929 cells were exposed to titrated amounts of TNF-GFP or 
TNF, and viability was determined  (XTT assay, OD at 450 nm). f mean of 2 experiments. g, 
J558LTNF-GFP-IND tumours imaged as in c. (see also Extended Data Fig. 7 and Supplementary 
Information Video 4). h, Quantification of changes in J558LTNF-GFP-IND tumour signal and 
blood vessel area over time. d and h, combined data (mean ± s.e.m.) of 2-5 areas per animal 
and time point of 3 mice with J558LIFNγ-GFP-IND and 4 mice with J558LTNF-GFP-IND tumours. 
The number of mice, replications and sample size for each experiment are also shown in 
Supplementary Table 3. 
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Material and Methods 
 
Expression vectors 
To construct the PIG (pCAGloxPSTOPloxP-IFNγR-IRES-GFP) plasmid, the IRES-GFP 
sequence from pMIG29 was excised with HincII. The resulting fragment was ligated into the 
blunt-ended KpnI site of pHMGmGIFR30 resulting in pHMG-mIFNγR-IRES-GFP. To replace 
the LacZ gene of pCAGloxPSTOPloxPZ31 with the IFNγR-IRES-GFP fragment, 
pCAGloxPSTOPloxP-Z was digested with BamHI, treated with Klenow fragment and thereafter 
the LacZ Gene was excised by digestion with NotI. Next, the IFNγR-IRES-GFP fragment was 
excised from pHMGmIFNγR-IRES-GFP using SmaI and NotI and was ligated into pCAG 
loxPSTOPloxP to generate pCAGloxPSTOPloxPIFNγR-IRES-GFP. 
The retroviral vector plasmid for inducible IFNγ expression, pMOV-IFNγ, has been 
described19. To obtain pMOV-IFNγ-GFP and pMOV-TNF-GFP, cDNA sequences encoding 
for GFP-tagged mIFNγ or mTNF, including a glycine-serine-linker (G4S)3 that is located 
between the cytokine and the GFP gene (replacing the cytokine 3’ untranslated region), were 
de novo synthesized by GeneArt (Regensburg, Germany). The de novo synthesized sequences 
(IFNγ-GFP: 1230 bp, TNF-GFP: 1470 bp) contained NotI and SalI sites for ligation into NotI 
and SalI sites of pMOV.1-T2.	  
 
Mice 
PIG mice were generated by excising the pCAGloxPSTOPloxPIFNγR-IRES-GFP expression 
cassette using KpnI and NotI. The 8891 bp fragment was gel purified and injected into the 
pronucleus of fertilized C57BL/6 oocytes. C57BL/6, IFNγRdel (strain no. 003288), IFNγdel 
(strain no. 002287), Rag1del (strain no. 002216), Rag2del (strain no. 008449) (referred to as 
Ragdel) and CMV-Cre mice (strain no. 006054) were obtained from the Jackson laboratories. 
TCR-I mice32 are transgenic for a T-cell receptor specific for SV40 Large T, epitope I, and 
were obtained from Jackson laboratories (strain no. 005236) and crossed to a Ragdel genetic 
background. FSP-Cre mice33 were provided by Eric G. Neilson (Northwestern University, 
Feinberg School of Medicine, Chicago) and were backcrossed for 10 generations to the 
C57BL/6 genetic background. Lys-Cre mice34 backcrossed to C57BL/6 genetic background 
(N10) were obtained from Simon Fillatreau (German Centre for Rheumatology Research, 
Berlin). PDGFB-CreER-IRES-GFP mice35 were backcrossed for 10 generations to the 
C57BL/6 genetic background. To obtain mice with cell type-specific expression of the 
IFNγR, PIG mice were crossed to the respective Cre strain (CMV-Cre, Lys-Cre, FSP-Cre, 
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PDGFB-CreER-IRES-GFP) and to IFNγRdel mice. PIGIFNγR-del x PDGFB-CreER-IRES-GFP 
were further crossed to IFNγdel mice. Mice used in experiments were heterozygous for the 
PIG and Cre alleles and homozygous for the IFNγRdel (and IFNγdel) allele. Rosa26-tdRFP 
mice were generated on the C57BL/6 genetic background36 and were crossed to PDGFB-
CreER-IRES-GFP mice. Irf4del mice37 were backcrossed for 10 generations to the C57BL/6 
genetic background. Irf4wt/del and Irf4del were obtained by breeding Irf4del male and Irf4wt/del 
female mice. Male and female mice aged between 6 - 24 weeks were used and matched in 
experiments. All animal experiments were conducted in accordance with institutional, state, 
and federal guidelines and with permission of the local animal ethics committee of the 
LAGeSo, Berlin. Effect and sample size estimates were done and included in animal 
experiment applications. At any signs of illness (lethargy, hunched posture, scruffy coat, 
social isolation, inactivity or weight loss) mice were taken out of the experiment. All animals 
used for experiments are reported. No randomization was performed. No investigator 
blindfolding was performed for animal experiments. 
 
Genotyping 
The PIG transgene was identified by PCR with primers specific for the stop cassette 
(chloramphenicol acetyltransferase gene) 5'-CAG TCA GTT GCT CAA TGT ACC-3' and 5'-
ACT GGT GAA ACT CAC CCA-3' and the GFP gene 5'-AAG TTC ATC TGC ACC ACC 
G-3' and 5'-TCC TTG AAG AAG ATG GTG CG-3'. The endogenous IFNγR gene was 
detected with a forward primer specific for exon 4: 5'-ATG CAA CGG TTT CCA CCC CC-
3', and a reverse primer in intron 4: 5'-CCA GTC ATA GCC GAA TAG CC-3'. IFNγRdel gene 
was detected with a forward primer specific for exon 4 (as above) and a reverse primer 
specific for the neomycin resistance gene 5'-CCA CCT CAG CAC TGT CTT CA-3'. IFNγdel 
mice were genotyped using the primers: oIMR6218 5'-CCT TCT ATC GCC TTC TTG ACG-
3', oIMR8284 5'-AGA AGT AAG TGG AAG GGC CCA GAA G-3' and oIMR8285	  5'-AGG 
GAA ACT GGG AGA GGA GAA ATA T-3'. Rosa26-RFP mice were genotyped by PCR 
using primers 5'-AAG ACC GCG AAG AGT TTG TCC-3', 5'-TAA GCC TGC CCA GAA 
GAC TCC-3' and 5'-AAG GGA GCT GCA GTG GAG TA-3'. The PDGFB-CreER-IRES-
GFP transgene was detected using primers 5'-GCC GCC GGG ATC ACT CTC G-3' and 5'-
CCA GCC GCC GTC GCA ACT C-3'. All other Cre-transgenic mice (Lys-Cre, FSP-Cre and 
CMV-Cre) were genotyped by using the generic Cre-PCR from the Jackson labs with the 
primers: oIMR1084 5'-GCG GTC TGG CAG TAA AAA CTA TC-3' and oIMR1085 5'-GTG 
AAA CAG CAT TGC TGT CAC TT-3'. The genotype of, Ragdel, TCR-I mice was confirmed 
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by flowcytometry of PBMC for T cells B cells (Ragdel and TCR-I) or for hematopoietic cells. 
The genotype for PIG x CMV-Cre, Lys-Cre, FSP-Cre, PDGFB-CreER-IRES-GFP was 
confirmed by flowcytometry assessing GFP. Irf4del mice are unable to generate IgM, therefore 
lack of serum IgM (determined by ELISA) classified irf4del animals. 
 
Cells 
MCA313 is a fibrosarcoma that was induced by s.c. injection of 25 µg methylcholanthrene 
(MCA) dissolved in sesame oil in an IFNγRdel mouse. MCA313IFNγ-IND and 16.113-999IFNγ-IND 
cells were generated by retroviral transduction with pMOV-IFNγ by standard procedures19. 
Cells were cloned by limiting dilution and selected for optimal IFNγ induction and no 
expression in the absence of dox. J558L is a BALB/c-derived plasmacytoma cell line. 
J558LTNF-GFP-IND and J558LIFNγ-GFP-IND cells were generated by retroviral transduction of 
J558L cells with pMOV-IFNγ-GFP or pMOV-TNF-GFP, cloned and selected as described 
above. J558LTNF-GFP-IND and J558LIFNγ-GFP-IND cells were additionally transduced with the 
retroviral vector pMFG-Cerulean22. B16-F10 is a mouse melanoma cell line isolated from 
C57BL/6 mice and L929 is a fibrosacroma cell line derived from a C3H/An mouse. 16.113 is 
a carcinoma cell line derived from the colon of LoxP-Tag mice38. 16.113-999 is an 
IFNγ−insensitive variant of 16.113 cell line39. All cell lines mentioned above were cultured in 
RPMI 1640 Medium with 10% FCS. Send.1 cells are polyoma middle T antigen immortalized 
endothelial cells from blood vessels of the skin. Send.1 cells were cultured in Dulbecco's 
modified Eagle's medium DMEM with 20% FCS. Fibroblasts were generated by cutting tail 
skin into small pieces and digesting them overnight in DMEM, 20% FCS containing 
collagenase II (1 mg/ml) and dispase (1 mg/ml) at 37 °C. Digestion was stopped by changing 
the medium (DMEM, 10% FCS). To generate immortalized fibroblasts from PIG mice, 
primary fibroblast cultures were transfected with the plasmid pCMV-Tagori40 and with the 
plasmid pBabe-puro using Lipofectamine 2000 (Life Technologies) according to the 
manufacturer’s instruction. Transfected fibroblasts were selected using 1 µg/ml puromycin. 
To rule out bacterial products synergising with TNF, J558L cells were negatively tested for 
the presence of mycoplasma by PCR using the Primers: 5'-TGC ACC ATG TGT CAC TCT 
GTT AAC CTC-3' and 5'-GGG AGC AAA CAG GAT TAG ATA CCC T-3'. No commonly 
misidentified cell line was used in the study. MCA313 are fibrosarcoma, J558L 
plasmocytoma and 16.113 are carcinoma cells that were distinguished by morphology in cell 
culture. No other authentication was used. 
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Culture and imaging of HUVECs  
Donor-pooled human umbilical vein endothelial cells (HUVECs, PromoCell, GmbH) were 
cultured in Endothelial Growth Medium 2 (Lonza, Ltd) according to manufacturer’s 
instructions for a maximum of 5 passages. For immunofluorescence and time lapse 
experiments, cells were plated on 18 mm coverslips or in Nunc Lab-Tek chambered 
coverglass #1.5 (ThermoFisher Scientific, Inc.) coated with 10 µg/ml bovine plasma 
fibronectin (Sigma-Aldrich, Co. Llc. cat. # F1141). Cells were treated with recombinant 
human IFNγ (PeproTech) every 24 h for a total of 4 days. In order to stain actin filaments for 
live cell experiments, 250 nM SiR-Actin was added to the cells 1 hour before the start of the 
imaging. For immunofluorescence analysis of HUVECs, cells were fixed and permeabilized 
for 1 min. with 0.3% glutaraldehyde (EM Grade, Electron Microscopy Sciences), 0.25% 
Triton X-100 in cytoskeleton buffer (CB: 10 mM MES pH 6.1, 150 mM NaCl, 5 mM EGTA, 
5 mM glucose, 5 mM MgCl2) followed by a second fixation step with 2% paraformaldehyde 
(Electron Microscopy Sciences) in CB for 10 min. The sample was quenched with 0.1% 
NaBrH4 for 7 min. and washed thrice with PBS for 10 min. The sample was incubated in 
blocking buffer (3% BSA in PBS) for 1 h and stained overnight with rabbit polyclonal anti-
human VE-cadherin antibody (Abcam, # ab33168) in blocking buffer. The sample was then 
incubated for 1 h with donkey anti-rabbit IgG conjugated to Alexa Fluor 647 and 250 nM 
phalloidin conjugated to Alexa Fluor 488 (ThermoFisher Scientific, Inc). Samples were 
mounted in Abberior Mount Solid mounting media (Abberior, GmbH). Imaging of HUVECs 
was performed on LSM 780 confocal microscope with Plan Apochromat 63x NA 1.4 Oil 
objective (Carl Zeiss). Time-lapse series with reflection-based autofocus were acquired using 
a custom written Visual Basic macro (Antonio Politi and Jan Ellenberg, EMBL Heidelberg), 
acquiring at least three positions per experiment per condition. Z-stacks covering the entire 
cell volume were acquired and maximum intensity projected. Live imaging was performed at 
37 °C under 5% CO2.  
 
Cytokine analysis 
2 x 105 MCA313IFNγ-IND, J558LTNF-GFP-IND or J558LIFNγ-GFP-IND cells/ml were cultured for 48 h 
without or in the presence of 10, 50, or 100 ng/ml dox (Sigma Aldrich). Culture supernatants 
were analysed by IFNγ- or TNF-specific ELISA according to the manufacturer’s (OptEIATM; 
BD Biosciences) recommendation. TNF biological activity of the TNF-GFP fusion protein 
was analysed by an L929 cytotoxicity assay. L929 cells were seeded at 3.5 x 104 cells in 96 
wells in RPMI, 2% FCS and cultured overnight. Then, 2 µg/ml Actinomycin D (Sigma 
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Aldrich) and recombinant TNF (Peprotech) or TNF-GFP in concentrations as indicated were 
added in fresh medium (RPMI, 2% FCS) and incubated for 24 h. Thereafter, fresh XTT 
(sodium,2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazoli-
um) solution was added, incubated for 4 h, and absorbance was measured at 450 nm. For each 
concentration, 3 replicates were tested per plate. To evaluate the bioactivity of the IFNγ-GFP 
fusion protein, 106 B16-F10 cells were cultured in 5 ml RPMI 1640 medium 10% FCS 
containing either recombinant IFNγ or IFNγ-GFP at a concentration of 1 ng/ml. After 48 h, 
MHC-I up-regulation was analysed by flowcytometry. Blood samples were collected from the 
facial vein using a sterile lancet. Blood was allowed to agglutinate and then centrifuged for 20 
min. at 4 °C. Serum samples were aliquoted and stored at -80 °C. To determine serum IFNγ 
levels, 20 µl serum were analysed using the cytometric bead array from eBioscience 
(Procartaplex) according to manufacturer’s instructions.  
 
Tumour experiments 
106 MCA313IFNγ-IND cells, 16.113-999IFNγ-IND, J558LTNF-GFP-IND or J558LIFNγ-GFP-IND cells were 
injected s.c. into the right flank of the mice. Tumours were measured 2-3 times weekly in 
three perpendicular diameters using a calliper and tumour volume was calculated using the 
ellipsoid volume formula (π/6 x a x b x c). According to the animal application approved by 
the local ethics committee (LAGeSo Berlin), animals were taken out of the experiment, if 
tumours reached an average diameter of 1.5-2 cm. In none of the experiments, a tumour 
reached a larger size. Mice with tumour necrosis were observed daily and monitored for 
humane endpoint criteria (lethargy, hunched posture, scruffy coat, social isolation, inactivity 
or weight loss) and in no case any of those exclusion criteria were detected. Dox was 
continuously administered by adding 1 mg/ml dox to light-protected drinking water 
(supplemented with 20 mg/ml glucose). Tamoxifen was administered via the chow at 400 
mg/kg (TAM400, LASvendi) three days before tumour cell transplantation as indicated. 
Before mice were exposed to tamoxifen chow, they were administered for 10 days soy-free 
chow from LASvendi to exclude effects from phytoestrogens.  
In experiments described in Fig. 1f and Extended Data Fig. 1a (left panel), dox was 
administered in 48 h intervals (48 h on dox, 48 h on water). In intravital imaging experiments, 
dox was administered by daily bolus injection of 10 µg i.p. For adoptive T-cell therapy, 106 
16.113 cells were s.c. injected into Ragdel mice. When tumours were established 
(approximately 500 mm3), mice received 107 TCR-I T cells from Ragdel x TCR-I mice i.v. per 
animal at the indicated time point. In the experiment described in the Extended Data Fig. 1h, 
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T cells from C57Bl/6 or IFNγdel mice were transduced with a retroviral vector to express the 
TCR-I T cell receptor. 5 days after ATT with 106 TCR-I-transduced T cells, tumours were 
isolated and after tissue digestion the number of endothelial cells was analysed by 
flowcytometry.  
For experiments in Extended Data Fig, 3d, Ragdel mice or Ragdel x IFNγRdel mice were 
reconstituted with 2 x 107 splenocytes from WT mice. Two weeks after T cell transfer, 106 
MCA313IFNγ-IND cells were injected and when tumours were established (846 ± 263 mm3), 
IFNγ was induced. 5 days after IFNγ induction tumours were isolated and after tissue 
digestion endothelial cells (CD31 and CD146 double positive cells) from 107 tumour cells 
were analysed by flowcytometry.  
Potential immunogenicity of transgenes used in this study was excluded by experiments 
showing that MCA313IFNγ-IND tumours grew and regressed after IFNγ induction with the same 
kinetics in WT and Ragdel mice (Extended Data Figure 1a) and, furthermore, cells expressing 
the rtTA protein were not eliminated even after 100 days in fully immunocompetent mice 
(Extended Data Figure 5f).  
 
Wound healing experiments 
106 MCA313IFNγ-IND cells were injected s.c. into the right flank of indicated mice. After one 
week (tumour size approximately 50 mm3), mice were anesthetized, and a wound of 5 mm in 
diameter was instilled on the back of the mice using a biopsy punch. For the first 48 h, 
analgesia was administered. Mice were inspected every day. The wound healing process was 
recorded by taking photos and by measuring the diameter of the wound in two perpendicular 
axes using a calliper. 
 
Gene expression analysis 
Tumour endothelial cells (CD31+/CD146+) were isolated by fluorescence-activated cell 
sorting into RNAzol®. cDNA was synthesized from ~500 pg total RNA according to the 
standard Affymetrix protocol GeneChip® WT Pico Kit (P/N # 902623) by using the 
Affymetrix T7 RNA polymerase promoter which is attached to random primers. Pre-IVT was 
performed with 12 amplification cycles. Then, ss-cDNA was fragmented and biotin-labelled 
according to Affymetrix recommendations. Fragmented cDNA (3.8 µg) was hybridized to 
MOGENE 2.0 ST arrays. Arrays were washed and stained in the Affymetrix Fluidics Station 
450 and further scanned using the Affymetrix GeneChip® Scanner 3000 7G. Software: 
Affymetrix GeneChip Command Console Version 4.0. The image data were normalized and 
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quality controlled with the Affymetrix Expression Console™ Software Version 1.4. The 
microarray data were deposited in the GEO data repository under the accession number 
GSE94504.  
The bioinformatics analysis of the gene expression data was carried out with R BioConductor, 
to quantify the gene expression changes and normalize array intensity values for the 
comparison between the samples we used “rma” function from “oligo” package 
(target=”probeset” parameter was used). Manufacturer’s probe identifiers were converted to 
mouse gene names with “mogene20stprobeset.db” annotation. After background subtraction 
and quantile normalization each gene intensity is determined as median of probe set 
intensities. Log fold changes are computed from the average across replicates. For 
MCA313IFNγ-IND data from 24 h and 48 h after induction were so consistent that they could be 
regarded as replicates (data not shown). Differential expression analysis was carried out with 
“limma” package by computing moderated t-statistics and Benjamini-Hochberg adjusted P-
values. Number of replicates (rep.) analysed were: MCA313IFNγ-IND 0 h 3-rep., MCA313IFNγ-
IND 24 h 2-rep., MCA313IFNγ-IND 48 h 2-rep., J558LIFNγ-GFP-IND 0 h 3-rep., J558L IFNγ-GFP-IND 24 
h 2-rep., normal kidney 0 h 3-rep., normal kidney 24 h 3-rep. WT T cells 5 days 3-rep., 
IFNγdel T cells 5 days 5-rep. 
 
Longitudinal imaging using window chambers 
The procedure to surgically implant window chambers and perform longitudinal imaging is 
detailed elsewhere22. In short, window chambers were implanted into mice, and mice were 
injected with 106 cancer cells. 13-18 days later, dox administration was started and continued 
throughout the experiment. For microscopic analysis, mice with window chambers were 
anesthetized using isofluorane. The window was fastened to the main stage of the microscope 
using a custom-made holder. The microscope (Leica SP5 II TCS Tandem scanner 2-photon 
spectral confocal with 4 x and 20 x /0.45 LWD IR objectives from Olympus) has a heated 
chamber for maintaining body temperature. The software and X-Y motorized stage allow 
returning to memorized positions within the window at later times. For visualization of the 
tumour vasculature and blood flow, mice were injected with 1,1-dioctadecyl-3,3,3,3-
tetramethylindodicarbocyanine perchlorate (DiD)-labeled red blood cells (RBC). Briefly, 
RBC were obtained from the peripheral blood of Ragdel mice and labelled with DiD 
(Invitrogen) for 30 min. at 37 °C. After 3 washes with PBS, DiD-labeled RBC were injected 
intravenously. Absorption and fluorescence emission maxima of DiD are 644 nm and 665 nm 
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respectively. The optical penetration of tissue typically ranged between 100-150 µm. The 
acquired images were analysed using Fiji41. 
 
Intravital 2-photon microscopy 
24 h prior to imaging procedure, 10 µg dox was injected i.p. in 100 µl PBS. In vivo 
multiphoton microscopy (IVMPM) of J558LIFNγ-GFP-IND tumours engrafted in Ragdel mice was 
performed while mice were anaesthetized with isoflurane. For IVMPM, an Ultima 
Multiphoton Microscopy System was used (Prairie Technologies). For imaging GFP, the 
excitation wavelength was set to l = 890 nm. Band-pass filters optimized for GFP (BP l = 
525/50 nm) were used for detection. Collected single plane images were assembled to a 3D 
stack for each tumour in silico using Amira 3D software. 
 
Transmission electron microscopy 
Tumour tissue was fixed by immersion in phosphate buffered 4% (w/v) paraformaldehyde 
and 1.25% (v/v) glutaraldehyde. Samples were postfixed with 1% (v/v) osmium tetroxide, 
dehydrated in a graded series of ethanol, and embedded in the PolyBed® 812 resin 
(Polysciences, Inc., Germany). 
Ultrathin sections (60-80 nm) were stained with uranyl acetate and lead citrate, and examined 
at 80 kV with a Zeiss EM 910 electron microscope (Zeiss, Oberkochen, Germany). 
Acquisition was done with a Quemesa CDD camera and the iTEM software (Emsis GmbH, 
Germany) and pictures were processed using Adobe Illustrator. 
 
Antibodies and staining reagents 
The following anti-mouse antibodies were used for flowcytometry: NK1.1 (clone PK136, 
Miltenyi Biotec # 130-102-400, isotype control mouse IgG2a # 130-091-835), CD8 (clone 53-
6.7, Biolegend # 100712, # 100708, isotype control rat IgG2a # 400508, # 400512), CD4 
(clone RM4-4, Biolegend # 116014, # 116006, isotype control rat IgG2b # 400612, # 
400608), CD3 (clone 145-2C11, Biolegend # 100336, isotype control Armenian hamster IgG 
# 400935), CD19 (clone 6D5, Biolegend # 115512, 115508, isotype control rat IgG2a # 
400512, # 400508), CD11b (clone M1/70, Biolegend # 101216, isotype control rat IgG2b # 
400618), GR-1 (Clone RB6-8C5, Biolegend # 108424, isotype control rat IgG2b # 400624), 
CD11c (clone N418, Biolegend # 117329, # 117308, isotype control Armenian hamster IgG # 
400935, # 400908), F4/80 (clone BM8, Biolegend # 123110, isotype control rat IgG2a # 
400508), CD119 (clone 2E2, Biolegend # 112804, isotype control Armenian hamster IgG # 
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400903), CD119 (clone 2E2, BD # 550482, isotype control Armenian hamster IgG1 # 
553970), CD31 (clone 390, eBioscience # 25-0311-82, Biolegend # 102418, isotype control 
rat IgG2a, k # 400522), CD146 (clone ME-9F1, Biolegend # 134704, isotype control rat 
IgG2a # 400508), CD146 (clone ME-9F1, Miltenyi Biotec # 130-102-739, isotype control rat 
IgG2a # 130-102-652), CD45.2 (clone 104-2, Miltenyi Biotec # 130-102-980, # 130-102-355,	  
isotype control mouse IgG2a # 130-098-898). Further reagents used for flowcytometry: 
viability dye eFluor® 450 or eFluor® 660 (eBioscience # 65-0863-18, # 65-0864-18), Faser-
kit APC (Miltenyi Biotec # 130-091-762), streptavidin-APC (Biolegend # 405207), 7-
aminoactinomycin (7AAD) (Biolegend # 420404). The following anti-mouse antibodies were 
used for confocal and fluorescence microscopy: GFP (Invitrogen # A-11122), CD11b (clone 
M1/70, abcam # 8788, isotype control rat IgG2b # ab18450), FAP (rabbit polyclonal IgG, 
abcam # 53066,), CD31 (clone MEC13.3, BD # 550274, isotype control rat IgG2a # 
553894), CD146 (clone ME9-F1,	  Biolegend # 134702, isotype control rat IgG2a # 400501) 
and F480 (BM8, Biolegend # 123102, isotype control rat IgG2a # 400501), ERG (abcam # 
196149, isotype # 199093), cleaved caspase 3 (cell signalling # 9604S), collagen 4 (AbD 
Serotec # 2150-1470). As secondary antibodies Alexa 488- (# A21206), Alexa 594- (# 
A21207 and # A21209), Alexa 568 (# A11077) - and Alexa 647- (# A31573 and # A21472) 
labelled: anti-rat IgG and anti-rabbit IgG (Life Technologies) were used. Hoechst 33342 was 
used for staining nuclei.  
 
Flowcytometry 
To analyse PBMC, blood was taken from the facial vein using a sterile lancet. Erythrocytes 
were lysed using ACK lysis buffer (BD Biosciences). To exclude dead cells from analysis, 7-
AAD or the fixable viability dye eFluor® 450 were used. For staining of tumour stroma cells, 
tumours were isolated, cut into small pieces and digested for 1 h in RPMI 1640 medium 
containing 10 mg/ml collagenase II, 10 mg/ml dispase and 10 µg/ml DNase I. Cells were 
washed in PBS and filtered over a 40 µm nylon mesh. Fc-receptors were blocked with anti-
CD16/32 blocking antibodies. To analyse tumour endothelial cells, we used an integrated 
magnetic enrichment, using anti-PE magnetic microbeads that were added to the sample of 
PE-positive cells (stained with CD31-PE-Cy7 / CD146-PE) and were directly enriched before 
FACS analysis, as suggested for analysis of rare cells when using the MACSQuant analyser. 
107 total cells from digested tumour material were stained with CD45.2, CD31, CD146 and 
live/dead cell exclusion. For IFNγR (CD119) staining, a biotin-labelled anti-CD119 (2E2) 
antibody in combination with streptavidin-APC was used, the signal was subsequently 
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enhanced by amplification using the FASER Kit-APC (Miltenyi Biotec) using streptavidin-
anti-APC antibodies. Control staining was done without the primary antibody. For 
intracellular staining of IRF4, anti-IRF4 mAb (Biolegend # 646408) and the transcription 
factor staining kit (eBioscience # 00-5523) was used. 
 
Nitric oxide synthase assay  
For isolating macrophages, tumours were cut into small pieces and digested as described 
above. Cells were washed in PBS and filtered over a 40 µm nylon mesh and labelled with 
anti-mouse CD11b MACS beads (Miltenyi Biotec). CD11b cells were purified by magnetic 
cell sorting (purity was > 90%). 4 x 105 CD11b cells were seeded in 12 well tissue culture 
plates. Cells were stimulated with 250 U/ml IFNγ for 24 h. The nitrite ion was measured in a 
Griess diazotization reaction using Griess reagent system (Promega) according to the 
manufacturer’s instructions. In short, 50 µl of medium was mixed with 50 µl of sulfanilamid 
solution and incubated for 10 min. protected from light. Next, Griess reagent (N-(1-
Naphthyl)ethylenediamine) was added and incubated for another 10 min. protected from light. 
Thereafter, absorbance was measured at 540 nm. NO concentration was determined using the 
OD value from the NO standard curve and medium without standard (blank) was set as 
detection limit.  
 
Immunohistochemistry 
Tumour tissues were fixed in 4% paraformaldehyde (Sigma Aldrich) containing 10% m/w 
sucrose overnight, incubated overnight in PBS-sucrose solution (25% m/w) and embedded in 
OCT-tissue tech (Sakura). 5 µm sections were mounted on slides. Slides were treated with 
0.2% galantine (Sigma Aldrich) and 0.2% Triton X-100 in PBS and additionally blocked with 
antibody diluent (Dako) for 1 h at RT. All antibody staining were performed in Dako antibody 
diluent solution. Primary antibodies were incubated overnight at 4 °C. After 3 times washing 
with PBS, 2nd antibodies were added for 1 h together with Hoechst 33342 (Sigma Aldrich) at 
room temperature. Negative controls were generated by staining with the 2nd antibodies and 
Hoechst 33342 only. After staining, the slides were covered with slowfade (Life 
Technologies) and analysed with ObserverD.1 or LSM710 confocal microscopes (Zeiss). 
H&E staining were performed on 5 µm paraffin embedded tissue sections. After de-
paraffinization and rehydration, sections were stained with haematoxylin (Gill no. 2) and 
eosin and covered with histomout and examined under an OberserverD.1 microscope with 
Zen software. For evaluation of erythrocytes, eosin fluorescence signals were captured and at 
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least 60 high magnification fields from 3-4 tumours were analysed for each experimental 
group. Analysis was performed using ZEN software (Zeiss), ImageJ (version 1.49) or Imaris.  
For VE-cadherin staining of tumour vasculature tissue sections were fixed using 2% 
paraformaldehyde in PBS for 15 min. at RT followed by three washes for 5 min. with PBS 
and 10 min. incubation in ice-cold methanol and another three washes for 5 min. with PBS. 
Image IT enhancer was employed for 30 min at RT followed rinsing in PBS and one wash for 
5 min with PBS. Blocking solution (PBS containing 10% goat serum and 2.5% mouse serum; 
Sigma) was used for 1 h at RT before staining procedure was started using anti-CD31 and 
anti-VE-cadherin (eBioscience # 14-1441-82) diluted 1:50 in blocking solution incubated on 
tissue sections over night at 4 °C in a wet chamber. Secondary antibodies diluted 1:100 in 
blocking solution containing Hoechst 33342 were incubated for 2-3 hours at RT. Mowiol was 
used as mounting medium after three finalizing washing steps with PBS for 5 min at RT. 
 
Statistics 
To estimate the effect size for those experiments not involving animals and presented in the 
paper, one pilot experiment was performed. Then, usually a second experiment powered on 
what was observed in the pilot experiment was performed to attain significance and to test 
reproducibility. Data in general met the assumptions of the tests performed. The variance was 
in general similar between the groups that were being statistically compared and data met the 
assumptions of the tests. Statistical analysis was performed with GraphPad Prism 5.0. When 
comparing two groups if not indicated otherwise, we used the two tailed Mann-Whitney-U-
Test. When comparing more than two groups, we used the one-way ANOVA test.  p values 
less than 0.05 were considered as significant, * P<0.05, ** P<0.01 and *** P<0.001. 
 
Data availability 
The datasets generated during the current study are available from the corresponding author 
on reasonable request. The custom written AFS Visual Basic macro for the time-lapse 
microscopy series with reflection based autofocus was developed by Antonio Politi and Jan 
Ellenberg (EMBL Heidelberg) and is available at http://www.ellenberg.embl.de/. The 
microarray data are available from the GEO data repository under the accession number 
GSE94504. 	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Extended Data Figures 
 
Tumour ischemia by IFNγ  resembles physiological blood vessel regression  
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Extended Data Figure 1: Release of IFNγ in established tumours leads to necrosis, tumour blood vessel reduction and tumour 
regression.  
 
Extended Data Figure 2: Mice with conditional IFNγR expression.  
 
Extended Data Figure 3: Cre-mediated recombination induces GFP expression in myeloid or in myeloid and fibroblastoid stroma 
cells of MCA313IFNγ-IND tumours in PIGLys-Cre mice and in PIGFsp-Cre mice respectively and IFNγ signalling in T cells does not 
contribute to reduction in CD31+/CD146+ tumour endothelial cells after IFNγ induction in established tumours.  
 
Extended Data Figure 4: Tamoxifen-induced, Cre-mediated recombination in MCA313IFNγ-IND tumour endothelial cells of PDGFB-
CreER-IRES-GFP x Rosa26-RFP mice and IFNγ-competent mice with IFNγR expression exclusively in endothelial cells show 
necrosis before IFNγ induction, but further reduction in blood vessel density and tumour regression after IFNγ induction.  
 
Extended Data Figure 5: GFP and IFNγR are expressed in MCA313IFNγ-IND tumour endothelial cells of PIGPdgfb-Cre-IFNγ-del mice. 
Tumours progressing after prolonged IFNγ exposure in these mice are largely necrotic but still produce IFNγ and wound healing 
is impaired in PIGPdgfb-Cre-IFNγ-del mice.  
 
Extended Data Figure 6: Induction of IFNγ-GFP fusion protein induces regression of established J558LIFNγ-GFP-IND tumours and 
blood vessels. 
 
Extended Data Figure 7: Induction of TNF-GFP fusion protein induces regression of established J558LTNF-GFP-IND tumours and 
bursting of blood vessels. 
 
Extended Data Figure 8: Erythrocyte extravasation after induction of TNF-GFP but not IFNγ-GFP. 
 
Extended Data Figure 9:  Activated blood vessels but not normal vessels regress upon IFNγ exposure and regression is 
accelerated in Irf4del mice. IFNγ derived from T cells induces similar changes in gene expression as IFNγ from J558LIFNγ-GFP-IND or 
MCA313IFNγ-IND cells. 
 
Extended Data Figure 10: IFNγ-mediated blood vessel regression in MCA313IFNγ-IND tumours in PIGPdgfb-Cre-IFNγ-del mice.   
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Extended Data Figure 1  ┃   Release of IFNγ  in established tumours leads to necrosis, blood vessel reduction and 
tumour regression. a-c, MCA313IFNγ-IND tumours d, h, 16.113 tumours and e-g 16.113-999IFNγ-IND tumours. a, Without IFNγ 
induction, MCA313IFNγ-IND tumours grow progressively (1st panel). Dox-induced IFNγ expression in established MCA313IFNγ-IND 
tumours (2nd panel) leads to tumour regression in WT but not IFNγRdel mice (3rd, 4th panel). Differences in tumour growth 
between “no dox” and “dox” groups in WT mice are statistically significant on days 19 (*) 23 (**) and 25 (***). IFNγ induction in 
WT mice at 642 ± 236 mm3 (the 2 crosses indicate mice that reached  a humane endpoint and were taken out of the 
experiment) and in IFNγRdel mice at 608 ± 130 mm3. No difference in tumour growth and IFNγ-induced tumour regression of 
MCA313IFNγ-IND tumours between Ragdel and Rag-competent hosts (5th panel Ragdel, n = 5, and 6th panel WT, n = 6). Dox 
administration at 1304 ± 290 mm3 on day 15. b, c, MCA313IFNγ-IND tumours without and 120 h after dox. b, Macroscopic image 
size bar 0.5 cm, and c, H&E staining (1st row), N and dotted line indicate necrotic area, (2nd row) immunohistology using anti-
CD31 mAb, size bars 100 µm. c, For H&E staining 3 animals per group with 4 to 5 areas were compared and differences are 
statistically significant (***). d, T cell-mediated rejection of 16.113 tumours. Mice (same as depicted in Figure 1c) were s.c. 
injected with 106 16.113 cells. On day 57, 107 TCR transgenic T cells specific for SV40-Large T, epitope I (TCR-I), expressed by 
16.113 tumour cells, were transferred when tumour size was 489 ± 253 mm³. Combined data from two experiments is shown (n 
= 16). e-g, Induction of IFNγ in established carcinomas leads to tumour regression and blood vessel reduction. e, Dox-
dependent IFNγ expression by 16.113-999IFNγ-IND cells in vitro, analysed by ELISA (mean values from two experiments are 
shown). f, Dox-induced IFNγ expression in established 16.113-999IFNγ-IND tumours grown in Ragdel mice leads to tumour 
regression and g, blood vessel reduction. The relative number of tumour endothelial cells (CD31+/CD146+) without and 120 h 
after IFNγ induction in tumours was determined from 107 tumour cells by flowcytometry. h, IFNγ released during T cell-mediated 
rejection of 16.113 tumours contributes to blood vessel reduction. Tumours were established as in d, and either not treated, 
treated with 106 TCR-I transduced T cells from either WT or IFNγdel mice. On day 5 after ATT, the relative number of tumour 
endothelial cells (CD31+/CD146+) was determined as in g. * P<0.05, ** P<0.01 and *** P<0.001.The number of mice, 
replications and sample size for each experiment are shown in Supplementary Table 3. 
 
Extended Data Figure 2 ┃Mice with conditional IFNγR expression. a, Schematic representation of transgenes combined to 
generate mice with conditional IFNγR expression. b and c, Functional IFNγR expression in PIGIFNγR-del fibroblasts upon Cre-
mediated excision of the stop cassette. b, Immortalized tail fibroblasts from PIGIFNγR-del mice were transfected with pBabe-puro-
Cre plasmid, selected for puromycin resistance and analysed for GFP and IFNγR (CD119) expression by flowcytometry. WT 
fibroblasts served as control. One representative out of 2 experiments is shown. c, IFNγ induces MHC I up-regulation in Cre-
transfected fibroblasts from PIGIFNγR-del mice. Flowcytometry of MHC I expression by fibroblasts from PIGIFNγR-del mice with (right 
panel) or without Cre-transfection (middle panel) (same fibroblasts as shown in b) that were cultured without (dotted line) or with 
1 ng/ml IFNγ for 48 h (black line). Fibroblasts from WT mice served as control (left panel). One representative out of 2 
experiments is shown. d, e, Cre-mediated recombination induces GFP expression in tumour stroma cells of PIGCmv-Cre, shown 
by immunohistology. MCA313IFNγ-IND tumours from d, PIGCmv-Cre and e, PIGIFNγR-del  mice. GFP signals were amplified by anti-GFP 
antibody and are shown in green, staining with antibodies as indicated in red, overlay in yellow and Hoechst staining in blue. 
Size bar 50 µm. The number of mice, replications and sample size for each experiment are shown in Supplementary Table 3. 
 
Extended Data Figure 3 ┃  Cre-mediated recombination induces GFP expression in myeloid or in myeloid and 
fibroblastoid stroma cells of MCA313IFNγ-IND tumours in PIGLys-Cre and in PIGFsp-Cre mice respectively and IFNγ  signalling 
in T cells does not contribute to reduction in CD31+/CD146+ tumour endothelial cells after IFNγ  induction in established 
tumours. a PIGLys-Cre  mice, b, c PIGFsp-Cre. a and c, Immunohistology. GFP signals were amplified by anti-GFP antibody and are 
shown in green, staining with antibodies as indicated in red, overlay in yellow and Hoechst staining in blue. Size bar 50 µm. b, 
Flowcytometry for GFP expression of primary tail fibroblasts from PIGIFNγR-del (n = 6) and PIGFsp-Cre  (n = 5) mice after 7 days of 
culture (mean 25.5 ± SD 12.8%). d, Ragdel (n = 6) or Ragdel x IFNγRdel mice (n = 5) were reconstituted with 2 x 107 splenocytes 
from WT mice. Two weeks after T cell transfer, MCA313IFNγ-IND cells were injected and IFNγ was induced when tumours were 
established (846 ± 263 mm3). 5 days after IFNγ induction, endothelial cells from 107 tumour cells were analysed by 
flowcytometry.	  ** P<0.01. The number of mice, replications and sample size for each experiment are shown in Supplementary 
Table 3. 
 
Extended Data Figure 4  ┃  a, b, Tamoxifen-induced, Cre-mediated recombination in MCA313IFNγ-IND tumour endothelial 
cells of PDGFB-CreER-IRES-GFP x Rosa26-RFP mice and c-g, IFNγ-competent mice with IFNγR expression exclusively 
in endothelial cells show necrosis before IFNγ  induction, but further reduction in blood vessel density and tumour 
regression after IFNγ  induction. a, Tumour sections of mice, treated with tamoxifen (upper left) or not (lower left), were 
stained with anti-CD31 antibodies (white). RFP expression (red) indicates tamoxifen-dependent recombination, GFP signals 
were amplified by anti-GFP antibody and are shown in green indicating PDGFB-promoter activity, overlay in yellow, Hoechst in 
blue. Panels to the right show single colours of the upper left panel. Size bar 50 µm. b, Flowcytometry of tumour-derived 
endothelial cells, gated on CD31+/CD146+ cells, of tamoxifen-treated (right panel) or non-treated mice (left panel) reveals 
recombination (RFP+ cells). For tamoxifen treated group, one representative out of 4 experiments is shown (mean 75.4 ± SD 
8.8%) RFP+ endothelial cells. c, In PIGPdgfb-Cre mice treated with tamoxifen, GFP expression (reflecting both PDGFB-promoter-
dependent Cre expression and excision of the stop cassette in PIGIFNγR-del mice) was detected in endothelial cells in MCA313IFNγ-
IND tumours.  d, MCA313IFNγ-IND tumours grew slower than in WT mice even without IFNγ  induction and e, became necrotic 
presumably because of low-level constitutive IFNγ present in the mice and primarily IFNγR expressing endothelial cells being 
able to consume it. Size bar 0.5 cm d, IFNγ  induction in established MCA313IFNγ-IND tumours in PIGPdgfb-Cre mice induced tumour 
regression, and f, g, reduction of endothelial cells. c, GFP expression in endothelial cells of MCA313IFNγ-IND tumours of PIGPdgfb-
Cre mice. GFP signals were amplified by anti-GFP antibody and are shown in green, staining with antibodies as indicated in red, 
overlay in yellow and Hoechst in blue. Mice received tamoxifen starting 3 days before cancer cell injection. Size bar 50 µm. d, 
Tumour regression following dox application (dox was given at a size of 509 ± 119 mm3 ; n = 5 no dox, and n = 6 with dox). e, 
Necrosis is visible in tumours before and is increased 120 h after dox-mediated IFNγ induction. f, Reduced blood vessel density 
in MCA313IFNγ-IND tumours of PIGPdgfb-Cre mice 120 h after dox-mediated IFNγ induction. Tamoxifen treatment and 
immunohistology as in c. Size bar 100 µm. g, Reduced numbers of CD31+/CD146+ cells in MCA313IFNγ-IND tumours 120 h after 
dox application. Endothelial cells from 107 tumour cells were analysed by flowcytometry (n = 3 no dox, n = 4 with dox).	  The 
number of mice, replications and sample size for each experiment are shown in Supplementary Table 3. 
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Extended Data Figure 5 ┃GFP and IFNγR are expressed in MCA313IFNγ-IND tumour endothelial cells of PIGPdgfb-Cre-IFNγ-del 
mice. Tumours progressing after prolonged IFNγ  exposure in these mice are largely necrotic but still produce IFNγ  and 
wound healing is impaired in PIGPdgfb-Cre-IFNγ-del mice. a, GFP is expressed in MCA313IFNγ-IND tumour endothelial cells. GFP 
signals were amplified by anti-GFP antibody and are shown in green, staining with antibodies as indicated in red, overlay in 
yellow and Hoechst in blue. Size bar 50 µm. b, CD119 (1st column) and GFP expression in tumour endothelial cells from 
PIGPdgfb-Cre-IFNγ-del mice treated (1st row, green histograms) or not treated with tamoxifen (2nd row, dotted line), PDGFB-CreER-
IRES-GFPIFNγR-del treated with tamoxifen (3rd row, blue histograms) and PIGIFNγR-del treated with tamoxifen (4rd row, blue 
histograms) confirms that only after tamoxifen application in PIGPdgfb-Cre-IFNγ-del mice both GFP and CD119 are induced. c, Since 
very few CD11b+ (7.5%) and NK1.1+ (4.2%) cells in the tumour stroma of PIGPdgfb-Cre-IFNγ-del were GFP+ (Supplementary Data 
Table 1b), NO production by tumour-derived CD11b+ cells as read-out for IFNγ responsiveness was analysed. 4 x 105 purified 
CD11b+ cells of MCA313IFNγ-IND tumours from mice as indicated were exposed to 250 U/ml IFNγ for 24 h, supernatants were 
mixed with Griess reagent and absorbance measured at 540 nm (dotted line shows detection limit) mean ± SD. d, H&E staining 
of a tumour section (from mice depicted in Fig. 2i) after around 50 days of IFNγ exposure. 1 representative of 4 mice is shown. 
e, Tumour of a mouse without dox (small central necrosis, 1 representative of 2 mice). Necrotic areas are encircled (dotted line). 
Size bar 2 mm. f, Progressing tumours still produce IFNγ. Tumours were reisolated after IFNγ induction from WT (n = 1, day 
116), PIGCmv-Cre (n = 3, day 92-116) and PIGPdgfb-Cre (n = 3, day 65-66). Reisolated tumour cells were cultured in 500 ng/ml dox 
for 48 h. Supernatants were analysed by IFNγ ELISA, mean ± SD. g, h, Impaired wound healing in PIGPdgfb-Cre-IFNγ-del mice. In the 
indicated mice bearing MCA313IFNγ-IND tumours (app. 50 mm3), a wound of 5 mm diameter was instilled. g, WT (n = 3), IFNγRdel 
(n = 3) and mice with endothelial specific IFNγR expression (n = 6) were dox-treated (circles) or left untreated (squares) WT (n = 
3) and IFNγRdel (n = 2) and mice with endothelial specific IFNγR expression (n = 4). Wound healing was recorded. Differences 
in mice with endothelial specific IFNγR became significant day 6 (*) and were highly significant day 18 (***). h, Representative 
pictures (WT day 14, IFNγRdel day 14, PIGPdgfb-Cre-IFNγ-del day 21). * P<0.05, ** P<0.01 and *** P<0.001.The number of mice, 
replications and sample size for each experiment are shown in Supplementary Table 3. 
 
Extended Data Figure 6┃  Induction of IFNγ-GFP fusion protein induces regression of established J558LIFNγ-GFP-IND 
tumours and blood vessels. a, 106 J558LIFNγ-GFP-IND cells were injected into Ragdel mice that were left untreated (left panel) or 
treated with dox (right panel) when tumours had a size of 461 ± 230 mm3. The crosses indicate mice that reached a humane 
endpoint and were taken out of the experiment (n = 10). b,  Window chamber imaging of a J558LIFNγ-GFP-IND tumour at low 
magnification. Same procedure as described in Fig. 3c. Two weeks established J558LIFNγ-GFP-IND tumour was imaged for 6 days. 
Blue, cancer cells; green, IFNγ-GFP fusion protein and right vascular network. One representative out of 3 experiments is 
shown. c and d, Quantification of histological analysis for CD31 and cleaved caspase 3 (CC3) staining, respectively. Each dot 
represents one field of view analysed by ImageJ. e, Representative CD31 and CC3 staining before and 120 h after dox. f, 
Quantification of ERG+ nuclei from immunohistology. g, Representative ERG staining before and 120 h after dox. Size bar 100 
µm. Three tumours with 4-6 fields of view were analysed.	  *** P<0.001.The number of mice, replications and sample size for 
each experiment are shown in Supplementary Table 3. 
 
Extended Data Figure 7┃  Induction of TNF-GFP fusion protein induces regression of established J558LTNF-GFP-IND 
tumours and bursting of blood vessels. a, 106 J558LTNF-GFP-IND cells were injected into Ragdel mice that were left untreated 
(upper panel) or treated with dox (lower panel) when tumours had a size of 611 ± 201 mm3. Tumours eventually relapsed due to 
selection of TNF-GFP loss variants (data not shown). (n = 9 no dox, and n = 10 with dox). b, Window chamber imaging of a 
J558LTNF-GFP-IND tumour at lower magnification. Same procedure as described in Fig. 3c. Two weeks established J558LTNF-GFP-IND 
tumour was imaged for 2 days. Blue, cancer cells; green, TNF-GFP fusion protein and right vascular network. One 
representative out of 4 experiments is shown. c and d, Quantification of histological analysis for CD31 and cleaved caspase 3 
(CC3) staining, respectively. Each dot represents one field of view analysed by ImageJ. e, Representative CD31 and CC3 
staining before and 120 h after dox. f, Quantification of ERG+ nuclei from immunohistology. g, Representative ERG staining 
without and 120 h after dox. Size bar 100 µm. Three tumours with 4-6 fields of view were analysed.	  ** P<0.01 and *** 
P<0.001.The number of mice, replications and sample size for each experiment are shown in Supplementary Table 3. 
 
Extended Data Figure 8┃Erythrocyte extravasation after induction of TNF-GFP but not IFNγ-GFP. a, J558LIFNγ-GFP-IND or 
J558LTNF-GFP-IND tumours were established for two weeks and mice were dox-treated for 48 h or left untreated. Then, tumour 
sections were stained with H&E. In the upper row light microscopy and in the lower row eosin fluorescence signals were 
captured. Shown are representative sections from tumours treated with dox for 48 h. Size bar = 100 µm. b, Quantification of 
erythrocytes in high magnification fields (HMF) using the ImageJ program. Number of analysed HMF: no dox IFNγ-GFP: 69 
HMF, 3 tumours; 48 h IFNγ-GFP: 97 HMF, 4 tumours; no dox TNF-GFP: 130 HMF, 3 tumours; 48 h TNF-GFP: 92 HMF, 4 
tumours. Groups were compared by unpaired t test.	  *** P<0.001.The number of mice, replications and sample size for each 
experiment are shown in Supplementary Table 3. 
 
Extended Data Figure 9┃  Activated blood vessels but not normal vessels regress upon IFNγ  exposure and regression 
is accelerated in Irf4del mice. IFNγ  derived from T cells induces similar changes in gene expression as IFNγ  from 
J558LIFNγ-GFP-IND or MCA313IFNγ-IND cells. a, No changes in blood vessel density in spleen and kidney after IFNγ induction. Anti-
CD31 staining of kidney and spleen sections after IFNγ induction in MCA313IFNγ-IND tumours grown in WT mice (n = 2). Size bars 
50 µm. b, Results of gene expression analysis as number of IFNγ-induced genes (log 2 fold change) in tumour endothelial cells 
of J558LIFNγ-GFP-IND tumours (n = 3), and kidney endothelial cells (n = 3). After IFNγ induction, there are more genes differentially 
regulated in kidney than in tumour endothelial cells. c, Venn-diagram showing the overlap between significantly differentially 
expressed genes (adj. P-value < 0.05) in endothelial cells of J558LIFNγ-GFP-IND, MCA313IFNγ-IND tumours (dox-treated vs. untreated) 
and 16.113 tumours after treatment with IFNγdel versus WT TCR-I T cells. d, Scatter plots of data from venn-diagram displaying 
changes of all genes presented (i.e. genes significantly deregulated in any of 3 comparisons). Endothelial cells from all three 
tumour types revealed strong similarity in regulated genes (Pearson correlation coefficients are calculated using all 410 genes). 
The union of 410 genes that were significantly differentially regulated in any of the three comparisons showed a correlation of 
approximately 0.8 across all 3 groups. Colours of dots match the colours of the numbers in the venn-diagram. The overlapping 
10 genes (red dots) are highly deregulated in all three comparisons. e, Representative images of untreated or IFNγ-treated (10 
ng/ml for 96 h) HUVECs, stained with phalloidin (green) and antibody against VE-cadherin (red). f, IRF4 is induced in mouse 
endothelial (SEND.1) cells 48 h after IFNγ (5 U/ml) treatment. Cells were stained with anti-IRF4 mAb, using transcription factor 
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staining kit, and analysed by flowcytometry (grey: isotype control, dotted line: without IFNγ, black line: IFNγ). g,  Endothelial cells 
from 107 MCA313IFNγ-IND cells grown in heterozygous Irf4wt/del or Irf4del mice that were treated with dox or left untreated. 
CD31+/CD146+ cells were analysed by flowcytometry. h, i, j, Immunohistology of MCA313IFNγ-IND tumours grown in heterozygous 
irf4wt/del or IRF4del mice, either treated or not with dox and stained for h, ERG, i,j, CD31 and cleaved caspase 3 (CC3). * P<0.05, 
** P<0.01 and *** P<0.001. The number of mice, replications and sample size for each experiment are shown in Supplementary 
Table 3. 
 
Extended Data Figure 10 ┃ IFNγ-mediated blood vessel regression in MCA313IFNγ-IND tumours of PIGPdgfb-Cre-IFNγ-del mice. 
a-c, Non-apoptotic vessel regression in MCA313IFNγ-IND tumours. a, Representative staining for ERG and cleaved caspase 
(CC3). Size bar 100 µm. b, ERG+ nuclei and c ERG+/ CC3+ cells. Quantification of histological analysis for d, CD31, f, CC3. e, 
Representative staining of CD31 and CC3. g, Quantification of histological analysis for collagen 4. h, Representative staining of 
CD31 and collagen 4 staining at 48 h at higher magnification. i, Representative staining of CD31 and collagen 4. White arrows 
in h and i indicate collagen 4 staining not associated with CD31 staining. Size bar 100 µm. j, Quantification of histological 
analysis for NG2. k, Representative staining of CD31 and NG2. In d ,f, g and j each dot shows one field of view analysed by 
ImageJ. l, Ratio of co-localization of NG2 and CD31. m, VE-cadherin, CD31 and Dapi staining without and 24 h after IFNγ 
induction. n, Electron microscopy analysis of blood vessels from MCA313IFNγ-IND tumours grown in PIGPdgfb-Cre-IFNγ-del mice. 
Electron micrographs show (left) non-occluded vessel and (right) occluded vessel. Lumen of capillaries (asterisks), erythrocytes 
(Er), endothelial cells (En) and macrophages (M) are labelled. Size bar 5 microns. o, Three tumours (for each two specimen) 
and in total 32 vessels without dox and 38 vessels after 48 h after dox were analysed by electron microscopy for vessel 
occlusion (bar diagram). ** P<0.01 and *** P<0.001. The number of mice, replications and sample size for each experiment are 
shown in Supplementary Table 3. 
 
 	  













